These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28412223)

  • 1. Bioengineered robust hybrid hydrogels enrich the stability and efficacy of biological drugs.
    Gil MS; Cho J; Thambi T; Giang Phan VH; Kwon I; Lee DS
    J Control Release; 2017 Dec; 267():119-132. PubMed ID: 28412223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin affibody-outfitted injectable gel enabling extended release of urate oxidase-albumin conjugates for hyperuricemia treatment.
    Cho J; Kim SH; Yang B; Jung JM; Kwon I; Lee DS
    J Control Release; 2020 Aug; 324():532-544. PubMed ID: 32454120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Pharmacokinetics and Pharmacodynamics of Intravenous Uricase Multivesicular Liposomes].
    Deng X; He D; Xiong HR; Zhou YL; Zhang JQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):688-91. PubMed ID: 26619536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanocapsules of therapeutic proteins with enhanced stability and long blood circulation for hyperuricemia management.
    Zhang X; Xu D; Jin X; Liu G; Liang S; Wang H; Chen W; Zhu X; Lu Y
    J Control Release; 2017 Jun; 255():54-61. PubMed ID: 28288895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase.
    Najjari A; Shahbazmohammadi H; Omidinia E; Movafagh AM
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):627-632. PubMed ID: 33639683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders.
    Lu J; Hou X; Yuan X; Cui L; Liu Z; Li X; Ma L; Cheng X; Xin Y; Wang C; Zhang K; Wang X; Ren W; Sun R; Jia Z; Tian Z; Mi QS; Li C
    Kidney Int; 2018 Jan; 93(1):69-80. PubMed ID: 28729031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of therapeutic protein and catalase-mimic nanoparticle using a biocompatible nanocarrier for enhanced therapeutic effect.
    Kim S; Kim M; Jung S; Kwon K; Park J; Kim S; Kwon I; Tae G
    J Control Release; 2019 Sep; 309():181-189. PubMed ID: 31356840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.
    Lim SI; Hahn YS; Kwon I
    J Control Release; 2015 Jun; 207():93-100. PubMed ID: 25862515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable biodegradable hydrogels.
    Nguyen MK; Lee DS
    Macromol Biosci; 2010 Jun; 10(6):563-79. PubMed ID: 20196065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
    Xiong H; Zhou Y; Zhou Q; He D; Deng X; Sun Q; Zhang J
    Nanomedicine; 2016 Aug; 12(6):1557-66. PubMed ID: 27013130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanosomal Microassemblies for Highly Efficient and Safe Delivery of Therapeutic Enzymes.
    Xiong H; Zhou Y; Zhou Q; He D; Wan S; Tan Q; Zhang M; Deng X; Zhang J
    ACS Appl Mater Interfaces; 2015 Sep; 7(36):20255-63. PubMed ID: 26325262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 3 hyperuricemia mouse models and evaluation of food-derived anti-hyperuricemia compound with spontaneous hyperuricemia mouse model.
    Xu Z; Sha W; Hou C; Amakye WK; Yao M; Ren J
    Biochem Biophys Res Commun; 2022 Nov; 630():41-49. PubMed ID: 36137324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramolecular distance in the conjugate of urate oxidase and fatty acid governs FcRn binding and serum half-life in vivo.
    Cho J; Park J; Kim S; Kim JC; Tae G; Jin MS; Kwon I
    J Control Release; 2020 May; 321():49-58. PubMed ID: 32006589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An injectable particle-hydrogel hybrid system for glucose-regulatory insulin delivery.
    Zhao F; Wu D; Yao D; Guo R; Wang W; Dong A; Kong D; Zhang J
    Acta Biomater; 2017 Dec; 64():334-345. PubMed ID: 28974477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
    Yang B; Kwon I
    Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A biohybrid hydrogel for the urate-responsive release of urate oxidase.
    Geraths C; Daoud-El Baba M; Charpin-El Hamri G; Weber W
    J Control Release; 2013 Oct; 171(1):57-62. PubMed ID: 23838153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity-masking delivery of uricase against hyperuricemia and gout.
    Ban Z; Sun M; Ji H; Ning Q; Cheng C; Shi T; He M; Chen X; Lu H; He X; Guo C; He Y; Shao D; He Y
    J Control Release; 2024 Aug; 372():862-873. PubMed ID: 38906421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
    Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
    Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable hydrogels for sustained release of therapeutic agents.
    Thambi T; Li Y; Lee DS
    J Control Release; 2017 Dec; 267():57-66. PubMed ID: 28827094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.